Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced an additional distribution agreement with Australian firm Sirtex Medical Ltd. The agreement involves Grand Pharmaceutical’s subsidiaries, Beijing Purevalley Biotechnology Co., Ltd, and Chengdu Purevalley Biotechnology Co., Ltd, which will exclusively distribute Sirtex’s SIR-Spheres (Y-90 microsphere) injection product within their respective regions in China.
Previous Deals and Financials
China Grand and Sirtex have a history of successful distribution collaborations. From 2022 to 2024, China Grand purchased products worth RMB 21.2 million (USD 2.93 million), RMB 52.17 million (USD 7.21 million), and RMB 101 million (USD 13.96 million) during each distribution agreement period. Under this new agreement, Beijing Purevalley and Chengdu Purevalley will purchase up to 800 and 200 sets of products from Sirtex, respectively, for resale, with a combined value capped at RMB 122.1 million (USD 16.87 million).
Acquisition and Market Expansion
China Grand acquired control of the SIR-Spheres product through the USD 1.4 billion purchase of Sirtex, which was completed in September 2018. The medical device, first approved in the US in 2003 for the treatment of unresectable metastatic liver cancer and metastatic liver tumors from primary colorectal cancer, entered the Hainan Boao Lecheng International Medical Tourism Pilot Zone in September 2021 through a special access scheme. The product received official market approval in China in February 2022, marking a significant milestone in its global expansion.-Fineline Info & Tech
Leave a Reply